Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 9/20 | 0.67 |
| ▸ | RAB9A | P51151 | 9/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102438 | 0.85 | MEN1 (0.80) | MEN1KMT2ATDP1LMNANPC1 | |
| SCHEMBL6300571 | 0.83 | KMT2A (0.83) | MEN1KMT2ATDP1LMNANPC1 | |
| SCHEMBL2009483 | 0.83 | SMN1; SMN2 (0.74) | MEN1KMT2ATDP1LMNANPC1 | |
| SCHEMBL6295702 | 0.83 | LMNA (1.00) | MEN1KMT2ATDP1LMNANPC1 | |
| SCHEMBL30739608 | 0.83 | LMNA (1.00) | MEN1KMT2ATDP1LMNANPC1 | |
| SCHEMBL4363732 | 0.83 | MEN1 (0.89) | MEN1KMT2ATDP1LMNANPC1 | |
| SCHEMBL4242557 | 0.83 | MEN1 (0.75) | MEN1KMT2ATDP1LMNANPC1 | |
| SCHEMBL7340253 | 0.82 | SMO (0.73) | MEN1KMT2ATDP1LMNANPC1 | |
| SCHEMBL3994741 | 0.81 | ALDH1A1 (0.76) | MEN1KMT2ATDP1LMNANPC1 | |
| SCHEMBL5237637 | 0.81 | HPGD (0.70) | MEN1KMT2ATDP1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691844-B2 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090105220-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | DENG XIAOHU | 2009-04-23 | — | — | US | disclosed |
| US-7365062-B2 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7238687-B2 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070135409-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070117790-A1 | 4-(2-fluorophenylbenzoyl-4-aminobenzoyl)-3'-(2-(N,N-dimethylaminoethylaminocarbonyl))-4-aza-[6,4]-spiro-[5,6]-benzoundec-2'-ene; inner ear disorders, hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-05-24 | — | — | US | disclosed |
| CN-1835926-A | Process for the preparation of nonpeptide substituded spirobenzoazepine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2006-09-20 | — | — | CN | disclosed |
| US-20060111567-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | CHEN ROBERT H | 2006-05-25 | — | — | US | disclosed |
| EP-1633721-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | disclosed |
| US-7001898-B2 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1307430-B1 | NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINES AS VASOPRESSIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005000819-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-12-23 | — | — | US | disclosed |
| EP-1307430-A1 | NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINES AS VASOPRESSIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20030045517-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002002531-A1 | NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINES AS VASOPRESSIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105220-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | REN, AVPR1B, WNK1 | MEN1 2498/4885KMT2A 2724/4885TDP1 4695/4885 |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | REN, AVPR1B, WNK1 | MEN1 2498/4885KMT2A 2724/4885TDP1 4695/4885 |
| US-20060111567-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | AVPR1B, AVPR2, AVPR1A | MEN1 3255/4885KMT2A 3607/4885TDP1 4627/4885 |
| US-20070135409-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | AVPR1B, AVPR2, AVPR1A | MEN1 3255/4885KMT2A 3607/4885TDP1 4627/4885 |
| US-20030045517-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | AVPR1B, AVPR2, AVPR1A | MEN1 3410/4885KMT2A 3343/4885TDP1 4642/4885 |
| US-20070117790-A1 | 4-(2-fluorophenylbenzoyl-4-aminobenzoyl)-3'-(2-(N,N-dimethylaminoethylaminocarbonyl))-4-aza-[6,4]-spiro-[5,6]-benzoundec-2'-ene; inner ear disorders, hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure | AVPR1B, AVPR2, BDKRB1 | MEN1 2633/4885KMT2A 2834/4885TDP1 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.